Last reviewed · How we verify
Brivaracetam oral solution
Brivaracetam oral solution, marketed by UCB Biopharma SRL, is an established treatment in the epilepsy market. The drug's key strength lies in its unique mechanism of action, which differentiates it from competitors. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Brivaracetam oral solution |
|---|---|
| Sponsor | UCB Biopharma SRL |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy (PHASE3)
- A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy (PHASE3)
- A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy (PHASE3)
- Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy (PHASE3)
- A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures (PHASE3)
- Bioequivalence Study of Two Brivaracetam Oral Solutions in Healthy Adults Under Fasting and High-Fat Meal Conditions (PHASE1)
- A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization (PHASE3)
- Efficacy Evaluation of Intravenous Brivaracetam and Phenytoin in Subjects With Nonconvulsive Electrographic Seizures (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Brivaracetam oral solution CI brief — competitive landscape report
- Brivaracetam oral solution updates RSS · CI watch RSS
- UCB Biopharma SRL portfolio CI